Universität zu Köln

Stahmeyer, Jona T., Rossol, Siegbert, Bert, Florian, Antoni, Christoph, Demir, Muenevver, Hinrichsen, Holger, Hueppe, Dietrich, Teuber, Gerlinde, Wiebner, Bianka, Wedemeyer, Heiner and Krauth, Christian (2014). Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. Eur. J. Gastroenterol. Hepatol., 26 (11). S. 1278 - 1286. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1473-5687

Full text not available from this repository.

Abstract

Background Viral hepatitis is major a public health problem affecting millions of people worldwide. Estimates assume 400 000-500 000 people chronically infected with hepatitis C virus (HCV) in Germany. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The aim of the study was to assess the costs for treating patients with chronic HCV in Germany. Methods We conducted a retrospective multicenter observational study. The design was approved by an ethics committee, and patients were asked for their informed consent. Patients were grouped in four different health states. Healthcare utilization data were extracted from doctor files of six medical centers in Germany. Results Data of 315 patients with chronic HCV were analyzed. The mean age was 49.4 years, 57.5% were male and 67.9% had a genotype 1 infection. The most common routes of transmission were injection drug use (39.0%) and infection through blood products (15.9%). The average total cost was (sic)19 147 including ambulatory care and diagnostics ((sic)1686), pharmaceuticals ((sic)14 875), inpatient care ((sic)1293), and sick leave ((sic)1293). For patients in stable health states (mild and moderate HCV, compensated cirrhosis), costs did not differ significantly and were mainly influenced by antiviral treatment. For patients with decompensated cirrhosis, inpatient care accounted for the largest part of the costs. Conclusion Treatment of HCV patients involves high costs, mainly associated with the length of antiviral therapy. Viral eradication can prevent severe disease stages, which are associated with high costs. It is necessary to follow current guidelines and monitor patients closely to avoid unnecessary costs. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Stahmeyer, Jona T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rossol, Siegbert UNSPECIFIED UNSPECIFIED UNSPECIFIED Bert, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Antoni, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED Demir, Muenevver UNSPECIFIED UNSPECIFIED UNSPECIFIED Hinrichsen, Holger UNSPECIFIED UNSPECIFIED UNSPECIFIED Hueppe, Dietrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Teuber, Gerlinde UNSPECIFIED UNSPECIFIED UNSPECIFIED Wiebner, Bianka UNSPECIFIED UNSPECIFIED UNSPECIFIED Wedemeyer, Heiner UNSPECIFIED UNSPECIFIED UNSPECIFIED Krauth, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-424973
DOI:	10.1097/MEG.0000000000000181
Journal or Publication Title:	Eur. J. Gastroenterol. Hepatol.
Volume:	26
Number:	11
Page Range:	S. 1278 - 1286
Date:	2014
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1473-5687
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SUSTAINED VIROLOGICAL RESPONSE; VIRUS-INFECTION; RESOURCE USE; EPIDEMIOLOGY; BOCEPREVIR; TELAPREVIR; METAANALYSIS; ASSOCIATION Multiple languages Gastroenterology & Hepatology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/42497